CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission
by on Friday, July 13th, 2012 | No Comments
Condition: Acute Myelogenous Leukemia
Interventions: Biological: CD3-/CD19- natural killer cells; Biological: CD3-CD56+ natural killer cells; Device: CliniMACS® CD3 and CD19 Reagent System; Device: CliniMACS® CD56 Reagent System; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Aldesleukin
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting – verified July 2012
See the article here: CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission